Abstract
Osteogenic sarcoma (osteosarcoma) is the most common primary tumor of bone. It accounts for approximately 19% of all malignant tumors of the bone. Of all the molecular targets altered during the genesis of osteosarcoma, the retinoblastoma gene (RB1) shows the highest frequency of inactivation. Published data from human osteosarcoma tumors and in vivo and in vitro model systems support a role for the retinoblastoma gene family in bone development and tumorigenesis. Although a variety of bone tumors, depending on the cell of origin, including osteoclasts or osteoclast-like cells, chondroblasts, and fibroblasts, are described, for the purpose of this review we will focus primarily on the tumors arising from the osteoblast lineage.
Keywords: Retinoblastoma tumor suppressor, osteosarcoma, osteoblast differentiation
Current Molecular Medicine
Title: The Retinoblastoma Protein in Osteoblast Differentiation and Osteosarcoma
Volume: 6 Issue: 7
Author(s): Amit Deshpande and Philip W. Hinds
Affiliation:
Keywords: Retinoblastoma tumor suppressor, osteosarcoma, osteoblast differentiation
Abstract: Osteogenic sarcoma (osteosarcoma) is the most common primary tumor of bone. It accounts for approximately 19% of all malignant tumors of the bone. Of all the molecular targets altered during the genesis of osteosarcoma, the retinoblastoma gene (RB1) shows the highest frequency of inactivation. Published data from human osteosarcoma tumors and in vivo and in vitro model systems support a role for the retinoblastoma gene family in bone development and tumorigenesis. Although a variety of bone tumors, depending on the cell of origin, including osteoclasts or osteoclast-like cells, chondroblasts, and fibroblasts, are described, for the purpose of this review we will focus primarily on the tumors arising from the osteoblast lineage.
Export Options
About this article
Cite this article as:
Deshpande Amit and Hinds W. Philip, The Retinoblastoma Protein in Osteoblast Differentiation and Osteosarcoma, Current Molecular Medicine 2006; 6 (7) . https://dx.doi.org/10.2174/1566524010606070809
DOI https://dx.doi.org/10.2174/1566524010606070809 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Stem Cells and their Management in Cancer Therapy
Recent Patents on Anti-Cancer Drug Discovery Current Advances in Retroviral Gene Therapy
Current Gene Therapy Genetic Variants in Genes Involved in Mechanisms of Chemoresistance to Anticancer Drugs
Current Cancer Drug Targets Current Drugs and their Therapeutic Targets for Hypoxia-inducible Factors in Cancer
Current Protein & Peptide Science Current Status and Future Perspective for Research on Medicinal Plants with Anticancerous Activity and Minimum Cytotoxic Value
Current Drug Targets Integrins as A New Target for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Bioactives from Marine Organisms and their Potential Role as Matrix Metalloproteinase Inhibitors
Current Pharmaceutical Design Peptide and Small Molecule Inhibitors Targeting Myeloid Cell Leukemia 1 (Mcl-1) as Novel Antitumor Agents
Current Molecular Medicine Targeting Key Transporters in Tumor Glycolysis as a Novel Anticancer Strategy
Current Topics in Medicinal Chemistry Strategies to Convert PACAP from a Hypophysiotropic Neurohormone Into a Neuroprotective Drug
Current Pharmaceutical Design Evaluation of <sup>177</sup>Lu-EDTMP in Dogs with Spontaneous Tumor Involving Bone: Pharmacokinetics, Dosimetry and Therapeutic Efficacy
Current Radiopharmaceuticals Challenges and Successes Using Nanomedicines for Aerosol Delivery to the Airways
Current Gene Therapy Recent Progress of Oridonin and Its Derivatives for the Treatment of Acute Myelogenous Leukemia
Mini-Reviews in Medicinal Chemistry APE1/Ref-1Role in Redox Signaling: Translational Applications of Targeting the Redox Function of the DNA Repair/Redox Protein APE1/Ref-1
Current Molecular Pharmacology Resisting the Resistance in Cancer: Cheminformatics Studies on Short- Path Base Excision Repair Pathway Antagonists Using Supervised Learning Approaches
Combinatorial Chemistry & High Throughput Screening Surface Markers of Cancer Stem Cells in Solid Tumors
Current Stem Cell Research & Therapy Bleomycin Induced Sensitivity to TRAIL/Apo-2L-Mediated Apoptosis in Human Seminomatous Testicular Cancer Cells is Correlated with Upregulation of Death Receptors
Anti-Cancer Agents in Medicinal Chemistry Combination Therapy of Chemotherapy or Radiotherapy and the Neurokinin-1 Receptor Antagonist Aprepitant: A New Antitumor Strategy?
Current Medicinal Chemistry Retrocyclins: Using Past as Prologue
Current Protein & Peptide Science Heterocyclic Scaffolds: Centrality in Anticancer Drug Development
Current Drug Targets